Handelsavisen
prelaunch
Companies Healthcare HUM.AX
HU
HUM.AX ASX Healthcare Services & Equipment

Humm Group Ltd

A$0,47
Open in Charts → Attach watcher ⌖
AUD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
237,1M AUD
P/E
5,7x
EV / Rev
7,4x
Div yield
7,14 %
Op margin
7,4 %
ROE
7,9 %
Net margin
5,9 %
Debt / equity
9,30
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

Humm Group Ltd operates as a consumer finance provider, generating revenue through interest and fees on consumer credit products.

Business. Humm Group Ltd (HUM.AX) is a healthcare services and equipment company headquartered in Australia. The firm is primarily listed on the Australian Securities Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification99 %
SectorHealth Care
Industry groupHealthcare Services & Equipment
Generated · model-assisted
Sell-side consensus
BUY2 analysts
2 buy0 hold0 sell
Avg 12m price target0,80

Analyst recommendations

2 analysts · consensus Buy
Buy2
Hold0
Sell0
12-month price target
0,80
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
5,7x
P/E
Analysts
Buy
2 analysts · indicative
Ownership
not yet wired
Profitability
7,9 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning HUM.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to HUM.AX. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR
    • Congressional trades
    • CongressLisa McClain — Humana Inc. Common Stock2025-10-31 · Republican · MI · Sale · $1,001 - $15,000
    • CongressLisa McClain — Humana Inc. Common Stock2025-10-30 · Republican · MI · Purchase · $1,001 - $15,000
    • CongressLisa McClain — Humana Inc. Common Stock2025-10-30 · Republican · MI · Sale · $1,001 - $15,000
    • CongressLisa McClain — Humana Inc. Common Stock2025-09-25 · Republican · MI · Purchase · $1,001 - $15,000
    • CongressLisa McClain — Humana Inc. Common Stock2025-06-24 · Republican · MI · Purchase · $1,001 - $15,000

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Humm Group Ltd (HUM.AX) is a healthcare services and equipment company headquartered in Australia. The firm is primarily listed on the Australian Securities Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification99 %
    SectorHealth Care
    Industry groupHealthcare Services & Equipment
    AI synthesis
    GENERATED

    Humm Group Ltd maintains a highly leveraged capital structure, with total liabilities of 4.84 billion AUD against total equity of 503.2 million AUD, resulting in a debt-to-equity ratio of 9.3. The company holds 4.68 billion AUD in long-term debt, which significantly exceeds its total assets of 5.34 billion AUD. Despite this leverage, the firm generates 179 million AUD in operating cash flow, though free cash flow is constrained to 12.2 million AUD after 21.3 million AUD in capital expenditures. The market values the equity at 227 million AUD, implying a price-to-book ratio of 0.45, suggesting the market prices the equity at a steep discount to its book value.

    Profitability metrics indicate modest returns on capital. The company reports a net income of 39.6 million AUD on revenue of 666.6 million AUD, yielding a net margin of approximately 5.9%. Return on equity stands at 7.87%, while return on assets is 0.74%. The operating income of 49.5 million AUD reflects an operating margin of roughly 7.4%. The gross profit of 330.5 million AUD suggests significant cost of goods sold or interest expense deductions before operating leverage is fully realized.

    Revenue concentration and segment details are not explicitly provided in the available data, limiting the ability to assess specific product or geographic exposure. The company’s total revenue of 666.6 million AUD serves as the primary top-line metric, with no further breakdown of segment contributions or regional splits available for analysis.

    Growth trajectory analysis is limited by the absence of historical period data in the current input. Without prior year or quarterly comparisons, year-over-year revenue or earnings growth rates cannot be calculated. The current snapshot provides a static view of the financial position, precluding trend analysis of revenue expansion or contraction.

    Risk assessment highlights medium liquidity risk and low dilution risk. A key flag notes that net cash is negative after subtracting total debt, emphasizing the reliance on debt financing. The high debt-to-equity ratio of 9.3 amplifies financial risk, particularly in rising interest rate environments. The low dilution risk suggests that share count stability is maintained, with basic and diluted shares outstanding both at 504.4 million.

    Recent observations indicate strong analyst sentiment, with a mean recommendation of 1.50 (strong buy) and a mean price target of 0.80 AUD, significantly above the current market price of 0.45 AUD. The high price target of 0.85 AUD and low of 0.75 AUD suggest a consensus view of substantial upside potential. No specific filing, news, or transcript events are detailed in the available data to explain recent market movements or strategic shifts.

    Key takeaways
    • The company trades at a significant discount to book value (P/B 0.45) despite high leverage (D/E 9.3).
    • Analyst consensus suggests substantial upside, with a mean price target of 0.80 AUD versus the current 0.45 AUD.
    • Free cash flow is thin at 12.2 million AUD, constrained by high capital expenditures relative to operating cash flow.
    • Net income of 39.6 million AUD yields a modest ROE of 7.87%, reflecting the capital-intensive nature of consumer finance.
    • Dilution risk is low, with no difference between basic and diluted share counts.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 3

    FY2025 net income surged 457.7% year-over-year to AUD 39.6 million, signaling a robust return to profitability.

    Free cash flow turned positive in FY2025, reaching AUD 12.2 million after three years of negative generation.

    Revenue grew at a 10.7% compound annual growth rate over the four-year period ending FY2025.

    BEAR CASE · 5

    The company carries a high credit risk flag, indicating significant concerns regarding its debt servicing capabilities.

    Debt-to-equity ratio of 9.3 places Humm in the bottom quartile of its peer cohort.

    Return on equity of 7.9% falls below the cohort median of 11.3%, suggesting inefficient capital utilization.

    Long-term debt increased to AUD 4.68 billion in FY2025, reflecting a heavy leverage burden.

    Return on assets of 0.74% indicates minimal profitability relative to the total asset base employed.

    In focus — financials by report

    Annual
    ANNUALFiled 2025-08-28
    FY 2025 · Full-year highlights

    Revenue A$666.6M, +7,6% YoY; Operating income +503,7% YoY.

    RevenueA$666.6M+7,6 % YoY
    Operating incomeA$49.5M+503,7 % YoY
    Net incomeA$39.6M+457,8 % YoY
    Free cash flowA$12.2M+339,2 % YoY
    EPS
    Operating cash flowA$179.0M+126,2 % YoY
    Financials
    Income statement
    RevenueA$666.6M
    Gross profitA$330.5M
    Operating incomeA$49.5M
    Net incomeA$39.6M
    Margins
    Gross margin49.6%
    Operating margin7.4%
    Net margin5.9%
    FCF margin1.8%
    Balance sheet
    Total assetsA$5.34B
    Total liabilitiesA$4.84B
    Total equityA$503.2M
    Cash & equivalents
    Long-term debtA$4.68B
    Cash flow
    Operating cash flowA$179.0M
    CapEx-A$21.3M
    Free cash flowA$12.2M
    SBC
    P&L flow · revenue → net income
    Revenue A$666.6MOperating costs A$617.1MNet income A$39.6M
    Highlights
    • Revenue A$666.6M, +7,6% YoY
    • Operating income +503,7% YoY
    • Net income +457,8% YoY
    • Free cash flow +339,2% YoY
    • Net margin 5.9%

    Valuation FY

    Market price
    A$0,47
    Market cap
    A$227.0M
    Enterprise value
    A$4.91B
    P/E
    5.7x
    Non-GAAP P/E
    EV / Revenue
    7.4x
    EV / Op income
    99.1x
    EV / OCF
    27.4x
    P / B
    0.5x
    P / Tangible book
    0.5x
    Tangible book
    A$503.2M
    Net cash
    -A$4.68B
    Current ratio
    Debt / equity
    9.3
    ROA
    0.7%
    ROE
    7.9%
    Cash conversion
    452.0%
    CapEx / revenue
    -3.2%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryHealthcare Services & Equipment1 272,5B node revenueUNH 35,2%CI 21,6%ELV 15,7%CNC 13,7%HUM 10,2%MOH 3,6%PGNY 0,1%
    Source: company disclosures · own-taxonomy revenue-covered set · attribution: collision-suspect (indicative)HUM 10,2% · rank #5 of 7

    Business relationships

    Business relationships1 disclosed relationship · 1 type · extracted from filings & disclosures
    Partners1
    Walmart IncWMT.OPartner100%Source ↗

    Supply chain

    Vendors → HUM ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSHUMHUMHumm Group Ltd1 entityWalmart IncFood Retail & DistributiUS
    1 mention in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-06-24

    Peer comparison

    Peer comparison6 peers · vs HUM · multiples and returns
    UN
    UNH
    UNITEDHEALTH GROUP INCORPORATED
    $415,60
    378,2B USD
    P/E
    33,7x
    -5,8 vs self
    Div yield
    2,0 %
    +1,0 vs self
    ROE
    11,6 %
    +5,2 vs self
    CI
    CI
    The Cigna Group
    $280,25
    74,0B USD
    P/E
    13,1x
    -26,5 vs self
    Div yield
    2,1 %
    +1,2 vs self
    ROE
    14,0 %
    +7,6 vs self
    EL
    ELV
    Elevance Health Inc
    $382,77
    83,9B USD
    P/E
    14,6x
    -24,9 vs self
    Div yield
    vs self
    ROE
    12,6 %
    +6,2 vs self
    CN
    CNC
    Centene Corp
    $64,45
    31,9B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -31,1 %
    -37,5 vs self
    MO
    MOH
    Molina Healthcare Inc
    $194,77
    9,9B USD
    P/E
    24,4x
    -15,2 vs self
    Div yield
    vs self
    ROE
    11,6 %
    +5,2 vs self
    PG
    PGNY
    Progyny Inc
    $31,53
    2,5B USD
    P/E
    34,0x
    -5,6 vs self
    Div yield
    vs self
    ROE
    11,3 %
    +5,0 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,06
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    2
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-07-27 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate0,06
    Revenueno estimateno estimate640,0M AUD
    Operating incomeno estimateno estimate18,2M AUD
    Full-year consensus mean (period as reported by source) · consensus in AUD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution2 analysts
    Strong buy1
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price targetA$0,80 · Median A$0,80
    Low A$0,75High A$0,85
    Operating income · consensus18,2M AUD
    EPS surprise
    +79,2 %
    reported vs consensus · beat
    Revenue surprise
    +4,2 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    LowA$0,75
    MeanA$0,80
    MedianA$0,80
    HighA$0,85
    SpotA$0,47
    +70.2 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin7,4 %Above P75
    Net Margin5,9 %Best in class
    ROE7,9 %Below median
    Capex / Rev-3,2 %Bottom quartile
    D/E9,30Bottom quartile
    Cash Conv4,52Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net disposed 489 sh1 exercises · 6 grants5 insiders
    • HILZINGER KURT JDirector · Restricted Stock Units → Humana CommonAcquired 233grant · 2026-06-30
    • HILZINGER KURT JDirector · Restricted Stock Units → Humana CommonAcquired 536grant · 2026-03-31
    • Renaudin George IIPresident, Insurance · Phantom Stock Units → Humana CommonAcquired 25other · 2026-03-31
    • Rechtin James A.President & CEO · Restricted Stock Units → Humana CommonDisposed 2 183exercise · 2026-01-08
    • Frederick Wayne A.I.Director · Restricted Stock Units → Humana CommonAcquired 766grant · 2026-01-02
    • Feinberg David TDirector · Restricted Stock Units → Humana CommonAcquired 70grant · 2025-12-31
    • Frederick Wayne A.I.Director · Restricted Stock Units → Humana CommonAcquired 35grant · 2025-12-31
    • Feinberg David TDirector · Restricted Stock Units → Humana CommonAcquired 29grant · 2025-12-31

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Price To Tangible Book
      market_price / (tangible_book_value / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Return On Equity
      net_income / total_equity
    • Enterprise Value
      market_cap - net_cash
    • Ev To Revenue
      enterprise_value / revenue
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    Source documents
    • Humm Group Ltd Market data — financials · 2026-07-27
    • Humm Group Ltd Market data — analyst estimates · 2026-07-27
    • Humm Group Ltd Market data — ESG · 2026-07-27
    • Humana Inc — company reference export (2026-07-05) · 2026-07-27

    Ownership & reference

    Leadership

    • Angelo DemasiChief Executive Officer, Executive Director

    Insider activity

    Net buying1 buys · 0 sellsnet $150K12 insiders · last 365d
    • Rechtin James A.President & CEO · Humana CommonOther 35 633 · 2026-05-01
    • Mehta JapanChief Information Officer · Humana CommonOther 9 448 · 2026-05-01
    • Mellet CelesteChief Financial Officer · Humana CommonOther 15 387 · 2026-05-01
    • Dintenfass DavidPresident, Enterprise Growth · Humana CommonOther 11 273 · 2026-05-01
    • O'Hara Michelle A.Chief Human Resources Officer · Humana CommonOther 10 485 · 2026-05-01
    • Field Robert StuartDirector · Humana CommonOther 852 · 2026-05-01
    • Ventura Joseph CChief Legal Officer · Humana CommonOther 10 318 · 2026-05-01
    • Shetty Sanjay KPresident, CenterWell · Humana CommonOther 9 945 · 2026-05-01
    • Martin AaronPresident, Medicare Advantage · Humana CommonOther 8 206 · 2026-05-01
    • Shetty Sanjay KPresident, CenterWell · Humana CommonOther 887 · 2026-04-01
    • Shetty Sanjay KPresident, CenterWell · Humana CommonOther 401 @ $175,44$70K · 2026-04-01
    • Felter John-Paul W.SVP, Chief Accting Off & Cont. · Humana CommonOther 84 @ $177,07$15K · 2026-02-24
    • Felter John-Paul W.SVP, Chief Accting Off & Cont. · Humana CommonOther 165 · 2026-02-24
    • Ventura Joseph CChief Legal Officer · Humana CommonOther 1 035 · 2026-02-24
    • Renaudin George IIPresident, Insurance · Humana CommonOther 1 035 · 2026-02-24
    • Ventura Joseph CChief Legal Officer · Humana CommonOther 478 @ $177,07$85K · 2026-02-24
    • Renaudin George IIPresident, Insurance · Humana CommonOther 419 @ $177,07$74K · 2026-02-24
    • Shetty Sanjay KPresident, CenterWell · Humana CommonBought 810 @ $185,21$150K · 2026-02-23
    • Felter John-Paul W.SVP, Chief Accting Off & Cont. · Humana CommonOther 5 669 · 2026-02-23
    • Dintenfass DavidPresident, Enterprise Growth · Humana CommonOther 1 182 @ $189,66$224K · 2026-02-21
    • Dintenfass DavidPresident, Enterprise Growth · Humana CommonOther 3 858 · 2026-02-21
    • Mellet CelesteChief Financial Officer · Humana CommonOther 7 763 · 2026-02-13
    • Mellet CelesteChief Financial Officer · Humana CommonOther 4 204 @ $181,46$763K · 2026-02-13
    • Mehta JapanChief Information Officer · Humana CommonOther 430 @ $181,46$78K · 2026-02-13
    • Mehta JapanChief Information Officer · Humana CommonOther 1 682 · 2026-02-13

    Short positioning

    4.3Mshares short-1.7% vs prior
    3.23days to cover
    48.1%short of daily vol
    13fails-to-deliver
    as of 2026-07-15 · short-interest report (free)
    Index membership
    S&P 500United States

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    HUM.AXCanonical
    ASX · AUD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.
    Relationship graph
    HUMWMT.OHealthcare Ser
    This companySectorPartners

    Evidence & claims

    From filings & derived data
    • Current ratio (FY 2025-12-31): 2.00xDerived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 5.2%Derived (calculated)
    • Return on equity (FY 2025-12-31): 6.7%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 7.8%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): 10.1%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): 5.5%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -68.9%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -1.6%Derived (calculated)
    • Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 11.0%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -1.4%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -1.4%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 89.1%Derived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): -5.0%Derived (calculated)
    • Debt-to-equity (FY 2025-12-31): 1.77xDerived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 3.8%Derived (calculated)
    • Return on assets (FY 2025-12-31): 2.4%Derived (calculated)
    • Net margin (FY 2025-12-31): 0.9%Derived (calculated)
    • EPS (diluted) (annual): USD-PER-SHARES 10SEC XBRL filing
    • Net income (annual): USD 1.19BSEC XBRL filing
    • Revenue (annual): USD 129.66BSEC XBRL filing
    • Current assets (annual): USD 32.73BSEC XBRL filing
    • Cash & equivalents (annual): USD 4.2BSEC XBRL filing
    • Total assets (annual): USD 48.91BSEC XBRL filing
    • Current liabilities (annual): USD 16.35BSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-30 07:17 UTCNEWSStockholm stocks open cautiously higher as mining sector leads early gains → Boliden and Epiroc drive early strength on the OMX Stockholm 30, while home security firm Verisure reacts to fresh half-year results.
    2026-07-30 04:36 UTCFILINGMaterial 8-K
    2026-07-30 04:36 UTCFILINGMaterial 8-K
    2026-07-29 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
    2026-07-27 07:45 UTCNEWSStockholm Stock Exchange Opens Higher on M&A Activity → Ambea's bid for Humana drives early gains as investors digest dual takeover offers at the start of the week.
    2026-07-24 07:15 UTCNEWSStockholm stocks open higher as Stillfront surges on earnings → Mobile gaming developer Stillfront leads the rally with double-digit gains following its financial report, helping offset Thursday's losses.
    2026-07-23 07:20 UTCNEWSStockholm stocks open lower as US tech weakness weighs on sentiment → The OMX Stockholm 30 dipped at the open, reversing the modest gains seen earlier in the week. Traton Group bucked the trend, rising on positive momentum from its Finnish peer.
    2026-07-22 07:28 UTCNEWSStockholm OMXS30 rebounds as Kambi and Dynavox surge → The broad index reversed early losses, driven by double-digit gains in gaming and assistive-tech names.
    2026-07-09 08:56 UTCNEWSStockholm stocks rally as engineering sector surges; Sivers plunges → Engineering firms led the Stockholm exchange higher on Wednesday, while Sivers Energy suffered a double-digit decline. The mixed session highlights diverging sentiment across the market.
    2026-07-02 09:27 UTCNEWSStockholm stocks open higher as SKF and Alleima lead gains → Swedish equities started the week on a positive note, with industrial names SKF and Alleima among the top performers, offsetting weakness in Asian markets.
    2026-07-01 07:08 UTCNEWSOslo Børs opens slightly higher as Aker shares rally on billion-dollar sale → Brent crude weakness weighs on the broader market, but Aker's stock surge offsets the energy drag in early Monday trading.
    2026-07-01 06:43 UTCNEWSABG Sundal Collier names Dometic, Karnov as M&A targets → The investment bank highlights profitable firms with depressed valuations as potential acquisition candidates, signaling renewed deal-making interest in the Swedish mid-cap space.
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-30INSIDERHILZINGER KURT J acquired 233 sh Restricted Stock Units — Director
    2026-06-29 09:58 UTCNEWSAmbea CEO signals more M&A despite rising debt after Humana bid → Mark Jensen says the animal health firm has the financial capacity for further deals, even as leverage increases following the move on competitor Humana.
    2026-06-29 09:38 UTCNEWSAmbea eyes further M&A after Humana bid: CEO Jensen → Ambea's chief executive signals an aggressive acquisition strategy continues, even as the company's debt load rises following its offer for rival Humana.
    2026-06-29 07:10 UTCNEWSStockholm market opens higher on dual M&A bids → Ambea's offer for Humana sparks a rally in the target's shares, lifting the broader index at the start of the week.
    2026-06-01FILING8-K filing →
    2026-05-19FILING8-K filing →
    2026-05-01 08:36 UTCFILINGRegulatory filing →
    2026-05-01 00:00 UTCINSIDER9 insider transactions — 2026-05
    2026-05-01 00:00 UTCINSIDER9 insider transactions — 2026-05
    2026-05-01INSIDERRechtin James A. transacted 35.6k sh Humana Common — President & CEO
    2026-05-01INSIDERMehta Japan transacted 9.4k sh Humana Common — Chief Information Officer
    2026-05-01INSIDERMellet Celeste transacted 15.4k sh Humana Common — Chief Financial Officer
    2026-05-01INSIDERDintenfass David transacted 11.3k sh Humana Common — President, Enterprise Growth
    2026-05-01INSIDERO'Hara Michelle A. transacted 10.5k sh Humana Common — Chief Human Resources Officer
    2026-05-01INSIDERField Robert Stuart transacted 852 sh Humana Common — Director
    2026-05-01INSIDERVentura Joseph C transacted 10.3k sh Humana Common — Chief Legal Officer
    2026-05-01INSIDERShetty Sanjay K transacted 9.9k sh Humana Common — President, CenterWell
    2026-05-01INSIDERMartin Aaron transacted 8.2k sh Humana Common — President, Medicare Advantage
    2026-04-29FILING10-Q filing →
    2026-04-29FILING8-K filing →
    2026-04-20FILING8-K filing →
    2026-04-10FILING8-K filing →
    2026-04-01 00:00 UTCINSIDER2 insider transactions — 2026-04
    2026-04-01 00:00 UTCINSIDER2 insider transactions — 2026-04
    2026-04-01INSIDERShetty Sanjay K transacted 887 sh Humana Common — President, CenterWell
    2026-04-01INSIDERShetty Sanjay K transacted 401 sh Humana Common — President, CenterWell ~$70k
    Showing the 40 most recent of 81 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage